Although several synthetic ERRα inverse agonists have been developed and have showed benefits in improving whole-body metabolism in obese and diabetic animal models49,59, there are no current ongoing NAFL/NASH clinical trials targeting ERRα. This evidence concerns the gene ESRRA and non-alcoholic fatty liver.